Results of a clinical trial show a lung cancer therapy using highly focused pulses with electrical energy show signs of immune responses that can treat the patients’ tumors. . . . → Read More: Electric Pulses Induce Lung Cancer Immune Response
|
|||||
Results of a clinical trial show a lung cancer therapy using highly focused pulses with electrical energy show signs of immune responses that can treat the patients’ tumors. . . . → Read More: Electric Pulses Induce Lung Cancer Immune Response A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties. . . . → Read More: Merger to Form Programmable Nano-Medicines Company The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness. . . . → Read More: Organ Chip Devices to Model for Radiation Sickness A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler. . . . → Read More: Start-Up Adapts Crispr for Molecular Detection, Raises $40M A developer of an auto-injection technology says its device can deliver a biologic drug under the skin in a fraction of the time of conventional syringes. . . . → Read More: High-Speed Biologic Injection Device Shown Feasible Venture investments in U.S. life science and biotechnology start-ups in the third quarter of 2023 rose from the previous two quarters to reach pre-pandemic levels. . . . → Read More: Infographic – Q3 Life Science Venture Funds Tick Up An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company. . . . → Read More: Longevity Science Group Spins-Off Biotech Start-Up A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program. . . . → Read More: Collapsed Microbiome Biotech Sells Off Assets A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round. . . . → Read More: Neuro Disease Biotech Gains $61M in Early Funds A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers. . . . → Read More: NIH Funds Antibody Discovery for Difficult Protein Targets |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |